vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Climb Global Solutions, Inc. (CLMB). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $182.4M, roughly 1.6× Climb Global Solutions, Inc.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 1.8%, a 94.5% gap on every dollar of revenue. On growth, Climb Global Solutions, Inc. posted the faster year-over-year revenue change (32.1% vs 9.4%). Over the past eight quarters, Climb Global Solutions, Inc.'s revenue compounded faster (40.7% CAGR vs 17.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Univar Solutions Inc. is a global chemical and ingredients distributor and provider of value-added services.
ACAD vs CLMB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $182.4M |
| Net Profit | $273.6M | $3.3M |
| Gross Margin | 90.8% | 14.5% |
| Operating Margin | 6.1% | 2.1% |
| Net Margin | 96.3% | 1.8% |
| Revenue YoY | 9.4% | 32.1% |
| Net Profit YoY | 90.3% | -9.5% |
| EPS (diluted) | $1.61 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $182.4M | ||
| Q4 25 | $284.0M | $193.8M | ||
| Q3 25 | $278.6M | $161.3M | ||
| Q2 25 | $264.6M | $159.3M | ||
| Q1 25 | $244.3M | $138.0M | ||
| Q4 24 | $259.6M | $161.8M | ||
| Q3 24 | $250.4M | $119.3M | ||
| Q2 24 | $242.0M | $92.1M |
| Q1 26 | — | $3.3M | ||
| Q4 25 | $273.6M | $7.0M | ||
| Q3 25 | $71.8M | $4.7M | ||
| Q2 25 | $26.7M | $6.0M | ||
| Q1 25 | $19.0M | $3.7M | ||
| Q4 24 | $143.7M | $7.0M | ||
| Q3 24 | $32.8M | $5.5M | ||
| Q2 24 | $33.4M | $3.4M |
| Q1 26 | — | 14.5% | ||
| Q4 25 | 90.8% | 15.4% | ||
| Q3 25 | 92.2% | 15.9% | ||
| Q2 25 | 92.2% | 16.5% | ||
| Q1 25 | 91.7% | 16.9% | ||
| Q4 24 | 91.6% | 19.3% | ||
| Q3 24 | 92.5% | 20.3% | ||
| Q2 24 | 92.5% | 20.2% |
| Q1 26 | — | 2.1% | ||
| Q4 25 | 6.1% | 4.9% | ||
| Q3 25 | 12.8% | 4.3% | ||
| Q2 25 | 12.2% | 5.0% | ||
| Q1 25 | 7.9% | 3.5% | ||
| Q4 24 | 59.1% | 7.2% | ||
| Q3 24 | 12.6% | 7.1% | ||
| Q2 24 | 12.6% | 4.6% |
| Q1 26 | — | 1.8% | ||
| Q4 25 | 96.3% | 3.6% | ||
| Q3 25 | 25.8% | 2.9% | ||
| Q2 25 | 10.1% | 3.7% | ||
| Q1 25 | 7.8% | 2.7% | ||
| Q4 24 | 55.4% | 4.3% | ||
| Q3 24 | 13.1% | 4.6% | ||
| Q2 24 | 13.8% | 3.7% |
| Q1 26 | — | $0.18 | ||
| Q4 25 | $1.61 | $1.51 | ||
| Q3 25 | $0.42 | $1.02 | ||
| Q2 25 | $0.16 | $1.30 | ||
| Q1 25 | $0.11 | $0.81 | ||
| Q4 24 | $0.86 | $1.52 | ||
| Q3 24 | $0.20 | $1.19 | ||
| Q2 24 | $0.20 | $0.75 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $41.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $118.4M |
| Total Assets | $1.6B | $458.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $41.8M | ||
| Q4 25 | $177.7M | $36.6M | ||
| Q3 25 | $258.0M | $49.8M | ||
| Q2 25 | $253.6M | $28.6M | ||
| Q1 25 | $217.7M | $32.5M | ||
| Q4 24 | $319.6M | $29.8M | ||
| Q3 24 | $155.1M | $22.1M | ||
| Q2 24 | $177.1M | $48.4M |
| Q1 26 | — | $118.4M | ||
| Q4 25 | $1.2B | $116.6M | ||
| Q3 25 | $917.3M | $109.3M | ||
| Q2 25 | $822.4M | $105.2M | ||
| Q1 25 | $765.2M | $95.6M | ||
| Q4 24 | $732.8M | $90.6M | ||
| Q3 24 | $577.2M | $87.7M | ||
| Q2 24 | $516.7M | $79.8M |
| Q1 26 | — | $458.8M | ||
| Q4 25 | $1.6B | $460.2M | ||
| Q3 25 | $1.3B | $376.1M | ||
| Q2 25 | $1.2B | $420.7M | ||
| Q1 25 | $1.1B | $370.1M | ||
| Q4 24 | $1.2B | $469.2M | ||
| Q3 24 | $976.9M | $371.9M | ||
| Q2 24 | $914.1M | $302.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-48.7M | $-11.9M | ||
| Q3 25 | $74.3M | $22.2M | ||
| Q2 25 | $64.0M | $-2.2M | ||
| Q1 25 | $20.3M | $8.5M | ||
| Q4 24 | $40.4M | $16.0M | ||
| Q3 24 | $63.2M | $-3.6M | ||
| Q2 24 | $25.0M | $7.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | -1.70× | ||
| Q3 25 | 1.03× | 4.73× | ||
| Q2 25 | 2.40× | -0.37× | ||
| Q1 25 | 1.07× | 2.30× | ||
| Q4 24 | 0.28× | 2.29× | ||
| Q3 24 | 1.93× | -0.66× | ||
| Q2 24 | 0.75× | 2.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
CLMB
Segment breakdown not available.
